LUZ V. ARROYO-CRUZ

Dr. LUZ V. ARROYO-CRUZ

Biology, University of Puerto Rico at Arecibo, Arecibo, USA
orcid
Assistant Professor of Industrial Microbiology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in ACS Omega
Verified
Journal Article
Open access
TLTaotao Ling
Taotao Ling
LUZ V. ARROYO-CRUZLUZ V. ARROYO-CRUZ
LUZ V. ARROYO-CRUZ
WSWilliam R. Smither
William R. Smither
ESEmily K. Seighman
Emily K. Seighman
Michelle M. Martinez-MontemayorMichelle M. Martinez-Montemayor
Michelle M. Martinez-Montemayor
FRFatima Rivas
Fatima Rivas
Ganoderma lucidum is a medicinal mushroom that produces various pharmacological compounds, including triterpenoids. A major bioactive component of G. lucidum is ergosterol peroxide (EP), which is attributed to its anticancer effects. The current study focuses on the in vitro ADME (absorption, distribution, metabolism, and elimination), in vivo efficacy and toxicity of EP, and the synthesis of new EP derivatives to improve aqueous solubility. It was found that EP is metabolically stable in liver microsomes and plasma. In vivo studies showed that EP inhibits tumor growth in murine cancer models, and it is well tolerated by mice. The maximum tolerated dose was investigated in mice at escalating doses with a defined maximum amount of 500 mg/kg, which indicated no signs of toxicity, confirmed by plasma chemistry and analysis of harvested tissues. Complementary organ toxicity assays including cardio and hepatotoxicity assays of EP demonstrated no inhibitory effects. Next, a focused library of EP derivatives was developed to investigate the iterative addition of heteroatoms to improve the aqueous solubility properties of EP. Significant solubility improvement was observed by the introduction of hydrogen bonding promoting groups, particularly the sulfate group. Superior aqueous solubility properties are directly correlated with the biological activity of the compound against triple-negative breast cancer cellular (TNBC) models. The EP derivatives maintain ample therapeutic index at the tested concentrations, indicating they engage with the same biological target(s) as the parental compound (EP). The combined studies indicate that EP and its derivatives are selective TNBC cell death inducers, while sparing noncancerous tissue.

Verified
Journal Article
Open access
PDF file
AAAliyah Lyam Bocachica Adorno
Aliyah Lyam Bocachica Adorno
AAAdriana Y. Aponte-Ramos
Adriana Y. Aponte-Ramos
PRPaola Sofía Rivera-Fuentes
Paola Sofía Rivera-Fuentes
NENatalia Paola Espinosa
Natalia Paola Espinosa
LUZ V. ARROYO-CRUZLUZ V. ARROYO-CRUZ
LUZ V. ARROYO-CRUZ
Michelle M. Martinez-MontemayorMichelle M. Martinez-Montemayor
Michelle M. Martinez-Montemayor
Ergosterol peroxide (EP) triggers apoptosis pathways by inducing reactive oxygen species (ROS) in TNBC cell lines. Excess ROS production is associated with major damage to mitochondria. We hypothesized that EP may act through ROS-induced mitochondrial dysfunction. Therefore, we performed a series of assays that assessed mitochondrial membrane potential (MMP), cellular respiration, and glycolysis in TNBC models. Cardiomyocytes derived from human-induced pluripotent stem cells were chosen as a non-cancerous model because of their high mitochondrial content. Two in vivo TNBC models were used to quantify the effect of EP on tumor volume and metastases. EP reduced MMP and disrupted mitochondrial functions exclusively in TNBC cells. In vivo EP was effective in reducing tumor volume without affecting liver function. There was also a significant decrease in metastasis to the lung, liver, and cancer stem cells following treatment. These results suggest EP is a promising therapy for TNBC.

1 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LUZ V. ARROYO-CRUZLUZ V. ARROYO-CRUZ
LUZ V. ARROYO-CRUZ
SSSebastián Sagardía-González
Sebastián Sagardía-González
KMKurt Miller
Kurt Miller
TLTaotao Ling
Taotao Ling
FRFatima Rivas
Fatima Rivas
Michelle M. Martinez-MontemayorMichelle M. Martinez-Montemayor
Michelle M. Martinez-Montemayor
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 expression. It is known for its high malignancy, invasiveness, and propensity for metastasis, resulting in a poor prognosis due to the absence of beneficial therapeutic targets. Natural products derived from mushrooms have gained significant attention in neoplastic therapy due to their potential medicinal properties. The therapeutic potential of Ganoderma lucidum in breast cancer has been highlighted by our group, suggesting its use as an adjuvant treatment. The present study aims to assess the potential antineoplastic capacity of two Caribbean native Ganoderma species found in Puerto Rico, Ganoderma multiplicatum (G. multiplicatum) and Ganoderma martinicense (G. martinicense). Antiproliferative studies were conducted via cell viability assays after cultivation, harvesting, and fractionation of both species. The obtained results indicate that most of the fractions show some cytotoxicity against all cell lines, but 33% of the fractions (F1, F2, F7, F12) display selectivity towards cancer cell models. We demonstrate for the first time that native Ganoderma species can generate metabolites with anti-TNBC properties. Future avenues will focus on structure elucidation of the most active fractions of these Ganoderma extracts.